Charles River Laboratories International, Inc. (NYSE:CRL) announced today the appointment of John Crowley to the role of Corporate Senior Vice President, Corporate Controller and Chief Accounting Officer, effective September 30. In this newly created position, Mr. Crowley will be responsible for providing strategic guidance to the finance groups, including directing the corporate accounting function and practices, maintaining its fiscal records and preparing its financial reports. He will also oversee the design and operation of the Charles River’s system of internal controls, ensuring compliance with the rules and regulations of the Sarbanes-Oxley Act.
Immediately prior to joining Charles River, Mr. Crowley was Vice President, Chief Accounting Officer & Corporate Controller of Ironwood Pharmaceuticals. Previously, he held senior corporate finance positions at Vertex Pharmaceuticals where he successfully managed and directed all areas of technical accounting.
James C. Foster, Chairman, President, and Chief Executive Officer of Charles River Laboratories, commented, “John brings a wealth of financial acumen to Charles River. His expertise and experience in the life sciences industry is a welcomed addition to our executive team.”
Mr. Crowley commented, “Charles River has a compelling value proposition and a unique business model. I look forward to playing an integral role in its future growth and success.”
Mr. Crowley holds a B.S. in both Economics and Accountancy from Babson College and is a certified public accountant.
Caution Concerning Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “will,” “may,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are based on Charles River’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 27, 2013, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release except as required by law.
About Charles River Laboratories
Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com
|Ameresco Names John R. Granara Vice President, Corporate Controller and Chief Accounting Officer (2013/9/9)|
|Clean Harbors Names Michael Battles SVP, Corporate Controller and Chief Accounting Officer (2013/9/26)|
|Teck Announces Appointment of Andrew Golding as Senior Vice President, Corporate Development (2013/9/13)|
|Forest Laboratories Names A. Robert D. Bailey Senior Vice President, Chief Legal Officer and General Counsel (2013/11/11)|
|Papa John’s Names Bob Kraut Senior Vice President and Chief Marketing Officer (2013/10/10)|
|Global Power Equipment Group Appoints Raymond K. Guba as Senior Vice President and Chief Financial Officer (2013/11/18)|
|8x8 Strengthens Management Team With Appointment of Darren Hakeman as Senior Vice President of Product & Strategy (2013/9/12)|
|Kulicke & Soffa to Appoint Yih-Neng Lee as Senior Vice President, Global Sales (2013/8/6)|
|Aimco Promotes Executive Vice President John Bezzant to Chief Investment Officer ()|
|Education Management Corporation Appoints Tyler D. Gronbach as Senior Vice President of Corporate Communications ()|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.